To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Expedition Therapeutics, Inc
Study ID
NCT07684820
Phase
PHASE2
Status
Recruiting

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Eligibility Criteria

Sex
ALL
Age
40 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • EXPD-101/FXS7553 Dose 1 — DRUG
    Oral tablet
  • EXPD-101/FXS7553 Dose 2 — DRUG
    Oral tablet
  • Placebo — DRUG
    EXPD-101/FXS7553 - matching oral tablet.

Study Details

This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

Key Dates

First listed
Jul 6, 2026
Start date
Jun 30, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2028
Completion
Jul 11, 2028

Study Design

Enrollment
600 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: EXPD-101/FXS7553 Dose 1
    Participants will receive EXPD-101/FXS7553 Dose 1, orally, once daily, for 52 weeks.
  • Experimental: EXPD-101/FXS7553 Dose 2
    Participants will receive EXPD-101/FXS7553 Dose 2, orally, once daily, for 52 weeks.
  • Placebo Comparator: Placebo
    Participants will receive a EXPD-101/FXS7553-matching placebo, tablets orally, once daily, for 52 weeks.

Primary Outcome Measure

Annualized rate of moderate and severe COPD exacerbations [ Time Frame: Over 52 Weeks ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
DM Clinical Research - PhoenixPhoenixArizona85012
Jade Perez
6232320800
Danielle Armas (PRINCIPAL_INVESTIGATOR)
California Medical Research Associates Inc.NorthridgeCalifornia91324
Chrismarie Goonarathne
8183491979
Jigar Kadakia (PRINCIPAL_INVESTIGATOR)
Lynn Institute of DenverAuroraColorado80012
Jessica Kovarna
303-322-0397
Timothy Colander (PRINCIPAL_INVESTIGATOR)
International Clinical ResearchAltamonte SpringsFlorida32701
Patrica Martinez
407-878-5830
Feldman (PRINCIPAL_INVESTIGATOR)
Nature Coast Clinical ResearchCrystal RiverFlorida34229
Donna Robinson
352-563-1865
Potu (PRINCIPAL_INVESTIGATOR)
Clinical Site Partners, LLC Leesburg dba Flourish ResearchLeesburgFlorida34748
Crystal Howell
888-688-8277
Suncoast Research Group, LLC Miami - Little Havana dba Flourish ResearchMiamiFlorida33135
Jaymie Marquez
3052557452
Mark Kutner (PRINCIPAL_INVESTIGATOR)
Optimal Research SitesOrangeFlorida32763
Janyssa Balmes
3862185911
Kristyna Paradis (PRINCIPAL_INVESTIGATOR)
Centricity Research ColumbusRinconGeorgia31326
Ashley King
8437255067308
Maria Mascolo (PRINCIPAL_INVESTIGATOR)
DM Clinical Research-IndianapolisIndianapolisIndiana46254
Stephanie Samayoa
4632713179
Brandon Essink (PRINCIPAL_INVESTIGATOR)
Cotton O'Neil Clinical Research CenterTopekaKansas66606
Ambrosee Wilkinson
7853680741
Najm Salah (PRINCIPAL_INVESTIGATOR)
Headlands Research Twin CitiesMaplewoodMinnesota55109
Kristina Smith
651-797-6886
McEvoy (PRINCIPAL_INVESTIGATOR)
Carolina Research Center, Inc.ShelbyNorth Carolina28150
Aimee Scronce
704 600-6052
Jones (PRINCIPAL_INVESTIGATOR)
Remington-Davis ResearchColumbusOhio43215
Ayriah Storms
6146853426
Cordasco (PRINCIPAL_INVESTIGATOR)
Clinical Research Associates of Central PA, LLCDuBoisPennsylvania15801
Mark Capichana
814 940-1212
Bansal (PRINCIPAL_INVESTIGATOR)
DM Clinical Research - PhiladelphiaPhiladelphiaPennsylvania19107
Michael Coyle
4453009011
David Wheeler (PRINCIPAL_INVESTIGATOR)
Horizon Clinical Research Group.CypressTexas77429
Lucia Sabido
2818415798
Dileep Puppala (PRINCIPAL_INVESTIGATOR)
DM Clinical Research- TomballTomballTexas77375
Maryam Jamil
2815170550
Mustafa Naeem (PRINCIPAL_INVESTIGATOR)
Burke Internal Medicine, Inc.BurkeVirginia22015
Amy Aziz
7034559711
Nashwa Gabra (PRINCIPAL_INVESTIGATOR)
Tidewater Clinical ResearchVirginia BeachVirginia23456
April Rusch
7574713375x111
Gaines (PRINCIPAL_INVESTIGATOR)

Find similar trials in Phoenix, AZ

Related Studies